|Day Low/High||4.06 / 4.35|
|52 Wk Low/High||2.80 / 7.80|
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C.
These under-$10 stocks are within range of triggering breakout trades.
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Keryx Biopharmaceuticals, Inc.
Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether Keryx Biopharmaceuticals, Inc.
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...
Trade-Ideas LLC identified Keryx Biopharmaceuticals (KERX) as a "perilous reversal" (up big yesterday but down big today) candidate
Lundin Law PC (the "Firm") announces that a class action lawsuit has been filed against Keryx Biopharmaceuticals Inc.
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Keryx Biopharmaceuticals, Inc.
Stocks with insider trader activity include CFFI, KERX and INCY
Trade-Ideas LLC identified Keryx Biopharmaceuticals (KERX) as a "dead cat bounce" (down big yesterday but up big today) candidate
Goldberg Law PC (the "Firm") announces that a class action lawsuit has been filed against Keryx Biopharmaceuticals Inc.
Keryx Biopharmaceuticals (KERX) stock is still declining Tuesday afternoon after the company's only approved medication experienced disruptions in production.
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Keryx Biopharmaceuticals Inc.
Lundin Law PC ( http://lundinlawpc.com/) announces it is investigating claims against Keryx Biopharmaceuticals Inc.
Levi & Korsinsky announces it has commenced an investigation of Keryx Biopharmaceuticals, Inc.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Keryx Biopharmaceuticals Inc. , where a total volume of 6,351 contracts has been traded thus far today, a contract volume which is representative of approximately 635,100 underlying shares (given that every 1 contract represents 100 underlying shares).